Please login to the form below

Not currently logged in

Cephalon gets green light for cancer pain drug in EU

The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora
The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora.

Effentora, a buccal tablet formulation of fentanyl, which is indicated for the treatment of breakthrough cancer pain (BTCP) can now be marketed in the 27 EU member states as well as Norway and Iceland.

Cephalon, a US-based biopharmaceutical company, is seeking to bolster its standing in the European healthcare market.

Alain Aragues, president of Cephalon Europe, said: "Cephalon continues to build its presence in Europe, the Middle East and Africa, and activities are ongoing to make Effentora available quickly in the EU member countries."

"We are committed to bring new medications to the European markets that address the needs of patients with cancer," he added.

15th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....